References
- H.R.34 – 114th Congress (2015–2016): 21st Century Cures Act. (2016, December 13). https://www.congress.gov/bill/114th-congress/house-bill/34.
- Lokugamage AU, Simpson FK, Chew-Graham CA. Patient commentary: How power imbalances in the narratives, research, and publications around long Covid can harm patients. BMJ. 2021;373:n1579.
- Bolislis WR, Fay M, Kühler TC. Use of real-world data for new drug applications and line extensions. Clin Ther. 2020;42(5):926–938.
- Beaulieu-Jones BK, Finlayson SG, Yuan W, et al. Examining the use of real-world evidence in the regulatory process. Clin Pharmacol Ther. 2020;107(4):843–852.
- Flynn R, Plueschke K, Quinten C, et al. Marketing authorization applications made to the european medicines agency in 2018–2019: What was the contribution of real-world evidence? Clin Pharma Therapeut. 2022;111(1):90–97.
- Jandhyala R. The effect of adding real-world evidence to regulatory submissions on the breadth of population indicated for rare disease medicine treatment by the European Medicines Agency. J Pharm Policy Pract. 2022;15(1):36.
- Ramamoorthy A, Huang SM. What does it take to transform real-world data into real-world evidence? Clin Pharmacol Ther. 2019;106(1):10–18.
- Jandhyala R. A medicine adoption model for assessing the expected effects of additional real-world evidence (RWE) at product launch. Curr Med Res Opin. 2021;37(9):1645–1655.
- Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther. 2019;106(1):36–39.
- Consultation document: MHRA draft guidance on randomised controlled trials generating real-world evidence to support regulatory decisions. GOV.UK. 2022; [cited 2022 Nov 21]. Available from: https://www.gov.uk/government/consultations/mhra-draft-guidance-on-randomised-controlled-trials-generating-real-world-evidence-to-support-regulatory-decisions/consultation-document-mhra-draft-guidance-on-randomised-controlled-trials-generating-real-world-evidence-to-support-regulatory-decisions.
- MHRA guidance on the use of real-world data in clinical studies to support regulatory decisions. GOV.UK. 2022; [cited 2022 Nov 21]. Available from: https://www.gov.uk/government/publications/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions.
- MHRA guideline on randomised controlled trials using real-world data to support regulatory decisions. GOV.UK. 2022; [cited 2022 Nov 21]. Available from: https://www.gov.uk/government/publications/mhra-guidance-on-the-use-of-real-world-data-in-clinical-studies-to-support-regulatory-decisions/mhra-guideline-on-randomised-controlled-trials-using-real-world-data-to-support-regulatory-decisions.
- Therapeutic Goods Administration. Real world evidence and patient reported outcomes in the regulatory context. Published online 2021; [cited 2022 Nov 21]. Available from: https://www.tga.gov.au/sites/default/files/real-world-evidence-and-patient-reported-outcomes-in-the-regulatory-context.pdf.
- Jandhyala R. The multiple stakeholder approach to real-world evidence (RWE) generation: observing multidisciplinary expert consensus on quality indicators of rare disease patient registries (RDRs). Curr Med Res Opin. 2021;37(7):1249–1257.
- Armstrong RA, Mouton R. Definitions of anaesthetic technique and the implications for clinical research. Anaesthesia. 2018;73(8):935–940.
- National Institute of Health and Care Excellence. NICE real-world evidence framework; Corporate document [ECD9]. 2022; [cited 2022 Nov 21]. Available from: https://www.nice.org.uk/corporate/ecd9/chapter/overview.
- US Food and Drug Administration. Framework for FDA’s Real-World Evidence Program. 2018; [cited 2022 Nov 21]. Available from: https://www.fda.gov/media/120060/download.
- European Medicines Agency. EMA Regulatory Science to 2025. 2020; [cited 2022 Nov 21]. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ema-regulatory-science-2025-strategic-reflection_en.pdf.
- Patino CM, Ferreira JC. Inclusion and exclusion criteria in research studies: definitions and why they matter. J Bras Pneumol. 2018;44(2):84.
- Morse JM, Mitcham C, Hupcey JF, et al. Criteria for concept evaluation. J Adv Nurs. 1996;24(2):385–390.
- Zumstein N, Riese F. Defining severe and persistent mental illness – a pragmatic utility concept analysis. Front Psychiatry. 2020;11:648.
- Pfadenhauer LM, Mozygemba K, Gerhardus A, et al. Context and implementation: a concept analysis towards conceptual maturity. Z Evid Fortbild Qual Gesundhwes. 2015;109(2):103–114.
- Setia S, Ryan NJ, Nair PS, et al. Evolving role of pharmaceutical physicians in medical evidence and education. Adv Med Educ Pract. 2018;9:777–790.
- Neutral theory: a conceptual framework for construct measurement in clinical research. (Pre-print)
- Jandhyala R. A novel method for observing proportional group awareness and consensus of items arising from list-generating questioning. Curr Med Res Opin. 2020;36(5):883–893.
- Jandhyala R. Delphi, non-RAND modified Delphi, RAND/UCLA appropriateness method and a novel group awareness and consensus methodology for consensus measurement: a systematic literature review. Curr Med Res Opin. 2020;36(11):1873–1887.
- Jandhyala R. Development of a definition for medical affairs using the Jandhyala method for observing consensus opinion among medical affairs pharmaceutical physicians. Front Pharmacol. 2022;13:842431. DOI:10.3389/fphar.2022.842431
- Jandhyala R. PAC-19QoL: design, validation and implementation of the post-acute (long) COVID-19 quality of life (PAC-19QoL) instrument. Health Qual Life Outcomes. 2021;19(1):229.
- Damy T, Conceição I, García-Pavía P, et al. A simple core dataset and disease severity score for hereditary transthyretin (ATTRv) amyloidosis. Amyloid. 2021;28(3):189–198.
- Freedman S, de-Madaria E, Singh VK, et al. A simple core dataset for triglyceride-induced acute pancreatitis. Curr Med Res Opin. 2022;39(1):37–46.
- Guest G, Bunce A, Johnson L. How many interviews are enough?: an experiment with data saturation and variability. Field Methods. 2006;18(1):59–82.
- Leese J, Li LC, Nimmon L, et al. Moving beyond “Untl saturation was reached”: critically examining how saturation is used and reported in qualitative research. Arthritis Care Res. 2021;73(9):1225–1227.
- Glaser BG, Strauss AL. The discovery of grounded theory: strategies for qualitative research. New York: Aldine; 1967.
- Forsyth D. 2009. Delphi technique. In: Levine J Hogg M, editors. Encyclopedia of group processes and intergroup relations. Thousand Oaks, CA: SAGE Publications, Inc.; pp. 195–197.
- Hills TT, Noguchi T, Gibbert M. Information overload or search-amplified risk? Set size and order effects on decisions from experience. Psychon Bull Rev. 2013;20(5):1023–1031.
- Storm NE, Chang W, Lin TC, et al. A Novel case study of the use of real-world evidence to support the registration of an osteoporosis product in China. Ther Innov Regul Sci. 2022;56(1):137–144.
- Varnai P, Davé A, Farla K, et al. The evidence reveal study: exploring the use of real-world evidence and complex clinical trial design by the european pharmaceutical industry. Clin Pharma Therapeut. 2021;110(5):1180–1189.
- Du Plessis D, Sake JK, Halling K, et al. Patient centricity and pharmaceutical companies: is it feasible? Ther Innov Regul Sci. 2017;51(4):460–467.
- Jandhyala R. Professional qualifications of medical affairs pharmaceutical physicians and other internal stakeholders in the pharmaceutical industry. F1000Res. 2022;11:813.
- Jandhyala R, Rout R. Observing expert opinion of medical affairs pharmaceutical physicians on the value of their clinical experience to the pharmaceutical industry using the Jandhyala method. Curr Med Res Opin. 2023. DOI:10.1080/03007995.2023.2165814.